Compare APYX & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | PRQR |
|---|---|---|
| Founded | 1982 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.0M | 185.4M |
| IPO Year | 1995 | 2014 |
| Metric | APYX | PRQR |
|---|---|---|
| Price | $3.70 | $1.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $6.50 | ★ $7.67 |
| AVG Volume (30 Days) | 99.6K | ★ 288.0K |
| Earning Date | 03-10-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.22 | $11.37 |
| Revenue Next Year | $6.74 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $1.08 |
| 52 Week High | $4.50 | $3.10 |
| Indicator | APYX | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 50.09 |
| Support Level | $3.25 | $1.65 |
| Resistance Level | $4.32 | $1.80 |
| Average True Range (ATR) | 0.25 | 0.11 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 59.60 | 39.00 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.